rs121909307
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM2PP5_Very_Strong
The NM_000178.4(GSS):c.491G>A(p.Arg164Gln) variant causes a missense, splice region change. The variant allele was found at a frequency of 0.0000787 in 1,613,160 control chromosomes in the GnomAD database, with no homozygous occurrence. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000039 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000083 ( 0 hom. )
Consequence
GSS
NM_000178.4 missense, splice_region
NM_000178.4 missense, splice_region
Scores
1
9
9
Splicing: ADA: 1.000
2
Clinical Significance
Conservation
PhyloP100: 4.99
Genes affected
GSS (HGNC:4624): (glutathione synthetase) Glutathione is important for a variety of biological functions, including protection of cells from oxidative damage by free radicals, detoxification of xenobiotics, and membrane transport. The protein encoded by this gene functions as a homodimer to catalyze the second step of glutathione biosynthesis, which is the ATP-dependent conversion of gamma-L-glutamyl-L-cysteine to glutathione. Defects in this gene are a cause of glutathione synthetase deficiency. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 20-34942488-C-T is Pathogenic according to our data. Variant chr20-34942488-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 8525.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GSS | NM_000178.4 | c.491G>A | p.Arg164Gln | missense_variant, splice_region_variant | 5/13 | ENST00000651619.1 | NP_000169.1 | |
GSS | NM_001322494.1 | c.491G>A | p.Arg164Gln | missense_variant, splice_region_variant | 5/13 | NP_001309423.1 | ||
GSS | NM_001322495.1 | c.491G>A | p.Arg164Gln | missense_variant, splice_region_variant | 5/13 | NP_001309424.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GSS | ENST00000651619.1 | c.491G>A | p.Arg164Gln | missense_variant, splice_region_variant | 5/13 | NM_000178.4 | ENSP00000498303.1 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152144Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
6
AN:
152144
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000321 AC: 8AN: 249356Hom.: 0 AF XY: 0.0000296 AC XY: 4AN XY: 135168
GnomAD3 exomes
AF:
AC:
8
AN:
249356
Hom.:
AF XY:
AC XY:
4
AN XY:
135168
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000828 AC: 121AN: 1461016Hom.: 0 Cov.: 32 AF XY: 0.0000798 AC XY: 58AN XY: 726872
GnomAD4 exome
AF:
AC:
121
AN:
1461016
Hom.:
Cov.:
32
AF XY:
AC XY:
58
AN XY:
726872
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152144Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74324
GnomAD4 genome
AF:
AC:
6
AN:
152144
Hom.:
Cov.:
32
AF XY:
AC XY:
2
AN XY:
74324
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
1
ALSPAC
AF:
AC:
1
ExAC
AF:
AC:
2
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Inherited glutathione synthetase deficiency Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 28, 2017 | The GSS c.491G>A (p.Arg164Gln) variant has been reported in three studies in individuals with 5-oxoprolinuria (a marker for glutathione synthetase deficiency), including two in a homozygous state, three in a compound heterozygous state with either another missense variant or a deletion variant, and in one heterozygote in whom the second variant was not identified (Shi et al. 1996; Tokatli et al. 2007; Li et al. 2015). The c.491G>A (p.Arg164Gln) variant was absent from 25 controls and is reported at a frequency of 0.00003 in the European (non-Finnish) population of the Exome Aggregation Consortium, though this is based on two alleles only in a region of good sequence coverage so the variant is presumed to be rare. Functional studies in individual fibroblasts and erythrocytes demonstrated that the variant resulted in a defect in splicing and enzyme activity of only 5% of normal levels. Expression of p.Arg164Gln variant cDNAs in both yeast and E. coli showed no detectable GSS activity and a failure to complement growth in yeast (Shi et al. 1996; Tokatli et al. 2007). Based on the collective evidence, the p.Arg164Gln variant is classified as pathogenic for glutathione synthetase deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 05, 2024 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 164 of the GSS protein (p.Arg164Gln). This variant also falls at the last nucleotide of exon 5, which is part of the consensus splice site for this exon. This variant is present in population databases (rs121909307, gnomAD 0.006%). This missense change has been observed in individual(s) with gluthathione synthetase deficiency (PMID: 8896573, 15717202, 25851806, 28822442). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 8525). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. Experimental studies have shown that this missense change affects GSS function (PMID: 8896573). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 23, 2016 | Variant summary: The GSS c.491G>A (p.Arg164Gln) variant causes a missense change involvign a conserved nucleotide, however, the variant is located at the last 3' position of the exon (Shi_1996), a known location to affect splicing, which 5/5 splice prediction tools predict an affect on splicing that is supported by a functional study, Shi_1996. The variant of interest was observed in the large, broad control population, ExAC, with an allele frequency of 2/117694 (1/58847), which does not exceed the estimated maximal expected allele frequency for a pathogenic GSS variant of 1/338. The variant of interest was observed in multiple affected individuals via publications in a homozygous or compound heterozygous state. GSS activity in these patients were significantly decreased (Shi_1996 and Njalsson_2005). In addition, a reputable database, OMIM, cites the variant as "pathogenic." Therefore, the variant of interest has been classified as "Pathogenic." - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 23, 2021 | The c.491G>A (p.R164Q) alteration is located in exon 5 (coding exon 4) of the GSS gene. This alteration results from a G to A substitution at nucleotide position 491, causing the arginine (R) at amino acid position 164 to be replaced by a glutamine (Q). However, this change occurs in the last base pair of coding exon4, which makes it likely to have some effect on normal mRNA splicing. Based on data from gnomAD, the A allele has an overall frequency of <0.01% (10/280724) total alleles studied. The highest observed frequency was 0.01% (8/127900) of European (non-Finnish) alleles. This variant has been detected as compound heterozygous and homozygous in multiple unrelated individuals with glutathione synthetase deficiency (Shi, 1996; Tokatli, 2007; Li, 2015). This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. In addition, as a missense alteration, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. - |
Glutathione synthetase deficiency with 5-oxoprolinuria Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Nov 01, 1996 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 05, 2019 | Published functional studies using complementation assays demonstrate a damaging effect (Shi et al., 1996); Predicted to destroy the natural spice donor site for intron 5 with skipping of exon 5 (Shi et al., 1996); This variant is associated with the following publications: (PMID: 11445798, 28822442, 17479648, 26669244, 15717202, 25851806, 8896573, 25525159) - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
D;.;D;D
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
.;D;.;D
M_CAP
Benign
D
MetaRNN
Uncertain
T;T;T;T
MetaSVM
Uncertain
T
MutationAssessor
Benign
L;.;L;L
PrimateAI
Benign
T
PROVEAN
Uncertain
N;.;.;.
REVEL
Uncertain
Sift
Benign
T;.;.;.
Sift4G
Benign
T;.;.;.
Polyphen
D;.;D;D
Vest4
MutPred
Loss of MoRF binding (P = 0.0248);Loss of MoRF binding (P = 0.0248);Loss of MoRF binding (P = 0.0248);Loss of MoRF binding (P = 0.0248);
MVP
MPC
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
dbscSNV1_RF
Pathogenic
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_DL_spliceai
Position offset: 0
Find out detailed SpliceAI scores and Pangolin per-transcript scores at